Breaking AI & Tech News Analyzed

The Global Bauxite Rush and Guinea's ContradictionIn the small village of Bembou Silaty, northwestern Guinea, 38-year-old Mamadou Aliou embodies the central contradiction of Guinea's bauxite boom. Working in the environmental health and safety department for a mining company while simultaneously advocating for his community's rights, Aliou represents the complex relationship between global resource demands and local realities."Before these companies arrived, we cultivated our land, and it sustained us," Aliou told Al Jazeera. "We could cover our daily needs, especially food. But now, when a piece of land is registered and belongs to a mining company, you have nothing there any more."The Strategic Value of Guinea's Bauxite ReservesGuinea holds the world's largest reserves of bauxite, the ore that becomes alumina and ultimately aluminum—a metal essential for car and aircraft frames, windows, wind turbines, and solar panels. Over the past three decades, the country has multiplied its bauxite production tenfold, with more than a dozen ongoing projects currently operating.As the global energy transition demands ever more aluminum, Guinea has found itself in a strategically crucial position. Approximately 75 percent of the bauxite exported by the country over the past decade has ended up in China, which produces 60 percent of the world's aluminum. Companies from Russia, the United States, and the United Arab Emirates have also established significant operations in the country to secure this valuable resource.Economic Disparities and Compensation ChallengesIn the traditional bauxite heartlands of Kindia and Boke, the main roads are notably well-maintained, and steady jobs in technical roles or transport logistics have created economic opportunities for some Guineans. In Bembou Silaty, however, the situation remains starkly different—a quiet village without electricity, where farming methods remain untouched by mechanization.People working in technical roles at the mine can earn up to about $300 a month, a significant sum in Guinea. For other locals who make a living from farming, most don't have a regular wage and rely on the yield from their crops. Across Guinea, an estimated half of the population depends on agriculture for their livelihood.Locals in Bembou Silaty say every hectare claimed by mining is a hectare lost to farming, in a country that spent more than $500m importing rice in 2024. "They give you compensation for your land, but it's not enough, and in the end, it's mismanaged," Aliou said. "Within a month or two, someone who received 50 or 100 million Guinean francs ($5,700-11,400) has nothing left. No land, no money. They have to start over, from below zero."Environmental Degradation and Water ContaminationThe environmental impact of bauxite mining in communities like Bembou Silaty has been profound. Not all homes in the village of about 5,000 have indoor toilets and plumbing. While a new water point serves nearly all residents, the water contains iron contamination.In neighboring villages, the situation is even more dire. "Since the mining companies came, we've had this problem with the water. The children get sick, and the parents too," said Mariama Kindi Diallo, a farmer. "The doctors tell us not to drink the rain or river water. There are no roads, no school, no phone signal. What are we supposed to do? We are asking for help to have a dignified life."Environmental concerns extend beyond water contamination. Surgical holes drilled into the ground mark where mining companies have tested for bauxite—a reminder to farmers that the impact on the land is felt even before extraction begins. In a recent report, Djami Diallo, the Guinean minister of the environment and sustainable development, stated that each year, certain companies had their impact studies and evaluation reports rejected for failing to comply with environmental standards.The Government's Push for Value AdditionTo address these challenges and increase the benefits for Guinea, the government of Mamady Doumbouya, which came to power in a 2021 coup, is attempting to reorganize the mining sector. It is pressing investors to process bauxite within Guinea, ensuring a portion of the value stays in the country.Processing bauxite into aluminum can multiply its price by 37 times. Instability in Iran amid the US and Israel's war has contributed to rising aluminum prices, which surpassed $3,600 per tonne in April. Doumbouya is set to lead the country for the next seven years, after winning the December 2025 elections with nearly 87 percent of the vote.Achieving this transformation, however, requires a huge increase in electricity generation—power that is non-existent in villages like Bembou Silaty and unreliable even in the capital, Conakry. Guinea is working with neighboring Senegal on a solution: Using Senegalese gas to generate enough electricity to process its bauxite on African soil.The Global Trail of Bauxite and MigrationThe story of Guinea's bauxite extends far beyond its borders. More than 3,000km away, in Parets del Valles, Spain, the journey's end plays out. For Spain, Europe's largest consumer of Guinean bauxite, more than 90 percent of its imports come from Guinea.The aluminium produced there feeds the automotive industry and serves both industrial and domestic purposes. In Spain, there is light, hot water, paved roads—all the base elements of a decent life that remain elusive in many parts of Guinea.Increasingly, more boats are leaving directly from Guinea, towards the Canary Islands and on to mainland Europe. According to Frontex, the European Union border security agency, more Guineans arrived in the Canary Islands, Spain, in 2023 (2,324) than in the previous 13 years combined. In 2024 and 2025 combined, another 6,000 Guineans arrived.Many left, following the bauxite trail, hoping to find something more in the places where their resources are both enjoyed and exploited. "If you compare the bauxite we export with what we get in return, the difference is enormous," Aliou reflects. "We gain almost nothing. Just enough to survive."

The Breakthrough in Breast Cancer TreatmentA landmark international study has revealed that millions of women with breast cancer could safely skip chemotherapy thanks to a genomic test that determines who needs the treatment and who doesn't. The randomised trial specifically examined whether the test could identify patients who would not benefit from chemotherapy, allowing them to avoid the potentially debilitating treatment without compromising their outcomes.The Scientific Evidence Behind the TestThe results of the Optima trial, which will be presented at the American Society of Clinical Oncology's annual meeting, are being hailed by experts as gamechanging. The five-year cancer-free survival rate was 93.7% in the group that skipped chemotherapy, which was statistically non-inferior to the 94.9% rate in patients randomly assigned to receive chemotherapy.The Prosigna genomic test analyzes the activity of 50 specific genes in tumor tissue to determine the molecular subtype and develops a risk of recurrence score to help doctors decide if chemotherapy is necessary. This precision medicine approach allows for personalized treatment decisions based on the unique characteristics of each patient's cancer.A Patient's Journey to Avoiding ChemotherapyKaren Bonham, a speech and language therapist from Swansea in Wales, was one of 4,429 patients with breast cancer recruited to the trial from countries including the UK, Norway, Sweden, Australia, New Zealand and Thailand. Diagnosed with cancer in 2017 at the age of 55 after routine breast screening, Bonham described the news as shocking."It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive," she said. Dreading chemotherapy, she agreed to join the Optima trial after undergoing surgery. She was only days away from starting treatment and had already cut her hair short when the results came back in September 2017.While taking a walk on a Welsh beach, Bonham received a phone call from her hospital informing her she had been allocated to the group of patients that would not be having chemotherapy. "How to describe the initial feeling? Immense relief? Like Christmas? Certainly a mixture of the two," she said.The Future of Personalized Cancer CareToday, Bonham, now 64, retired and living in Cardiff, is free of cancer, healthy and shows no signs of the disease coming back. "It is coming up to nine years since my diagnosis," she said. "I am mindful of my diagnosis, alert to potential changes in my body but do not feel defined by [it]. I walk, enjoy yoga and live well."While not every woman with breast cancer will be able to skip chemotherapy—the treatment remains necessary and important for many—the trial results suggest that genomic testing can safely identify those who can avoid it. This approach represents a significant shift toward personalized medicine in oncology, reducing unnecessary treatment and its associated side effects while maintaining excellent outcomes."I hope that the trial will bring positive patient outcomes to many," Bonham said, reflecting on the potential impact of this research on future breast cancer patients.

The RSF Attack on Civilians A force affiliated with the paramilitary Rapid Support Forces (RSF) has killed at least 27 people, including elderly residents, in an attack on villages west of Bara in Sudan's North Kordofan state, according to the Sudan Doctors Network. The Cairo-based medical NGO said the attacks took place on Thursday in the al-Murrah area, describing them as “a new crime targeting unarmed civilians in areas with no military presence”. The Humanitarian Crisis in Sudan Sudan has been engulfed in civil war since April 2023, when long-running tensions between the Sudanese army and the RSF erupted into a full-scale conflict that has killed hundreds of thousands of people and displaced millions. The Kordofan region has become one of the war's main battlegrounds, with fighting intensifying across several fronts, including through drone attacks. The Impact on Civilians The Sudan Doctors Network said that “targeting villages and civilian areas and executing citizens in such a brutal manner constitutes a flagrant violation of international humanitarian law and all norms and conventions that prohibit attacks on civilians, especially amid the catastrophic humanitarian conditions people are enduring because of the ongoing war”. The group added that the “continued attacks on civilians and safe villages” are worsening the humanitarian crisis and forcing more families into displacement, suffering and the loss of their livelihoods. The Food Security Situation The attacks come as more than 40 percent of Sudan's population faces acute hunger, according to a report released on Thursday by the United Nations-backed Integrated Food Security Phase Classification (IPC). The report said nearly 19.5 million people across the country are facing severe food insecurity as the conflict drives what aid agencies describe as one of the world's worst humanitarian crises. The Call to Action The Sudan Doctors Network also called on the “international community and human rights and humanitarian organizations to condemn these violations and act urgently to protect civilians and stop the repeated attacks on residential areas by pressuring RSF leaders to end violations against civilians”.

World Health Organization Director-General Tedros Adhanom Ghebreyesu confirmed on 31 May 2026 that five individuals infected with the rare Bundibugyo Ebola strain have recovered, including four who will be discharged today and one who left the hospital on Friday. The announcement came as the WHO opened a new treatment centre in Bunia, Ituri province, DRC.First Recoveries Confirmed in Bundibugyo Ebola OutbreakThe recoveries represent the first documented successes against a strain that has no approved vaccine or specific therapy. Doctors Without Borders (MSF) had described the situation as “deeply alarming” due to rapid case growth and diagnostic challenges.Outbreak Statistics Highlight Ongoing ThreatSuspected cases: ~1,000Suspected deaths: >220Current confirmed cases in DRC: rising rapidly across Ituri provinceCross‑border impact: Uganda reports 1 death and 9 casesThe Bundibugyo strain historically carries a case‑fatality rate of up to 50%, intensifying concerns about containment.Health System Strain and Regional Risks IntensifyLimited testing capacity and the absence of approved medical countermeasures have stretched local health infrastructure. MSF warned that the response has not yet caught up with the epidemic’s speed, and the outbreak’s proximity to the Ugandan border raises the risk of cross‑border transmission.Outlook: Vaccine Development and Containment ProspectsWhile the recoveries provide a morale boost, experts stress that sustainable control will depend on accelerated vaccine research, expanded diagnostic capacity, and coordinated regional surveillance. The WHO’s new treatment centre aims to improve patient outcomes, but long‑term containment will require international funding and rapid deployment of experimental therapeutics.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Rise of Nigeria's Digital Herbal Marketplace In Abuja, Nigeria, Oke Bola thought a fertility supplement she found online might help her conceive. Instead, within days of taking it, she struggled to breathe. Her experience reflects a growing online trade in unverified herbal remedies promoted across social media platforms. Bola, who is in her early 40s and has never had children, bought the supplement earlier this year and increased the recommended dosage, hoping for quicker results after hearing about it from friends and family. "I recognised the symptoms of asthma; the wheezing sound at night was familiar," she told Al Jazeera. "When I checked online, I realised it could be from the herbal medication." Her experience is not isolated. Across Nigeria, doctors and pharmacists report a surge in social media-driven self-medication, particularly involving unverified herbal products. This trend is worsening health outcomes, delaying treatment, and adding pressure to an already strained healthcare system serving about 230 million people. Nigeria's young, hyperconnected population increasingly uses digital platforms for health information and advice. But that access has also created what Dr Isaac Kolawole and Dr Fidelis describe as an "algorithmic apothecary" – an unregulated online marketplace where influencers and anonymous sellers promote remedies directly to consumers with little or no scientific backing. Health Impacts of Unverified Herbal Remedies Within this ecosystem, herbal remedies, long part of Nigeria's medical and cultural landscape, are increasingly repackaged as miracle cures, sometimes with dangerous consequences. Doctors report more patients arriving at hospitals only when their conditions have significantly worsened, often after prolonged use of unverified treatments. A consultant nephrologist at the University College Hospital in Ibadan, Dr Yemi Raji, said herbal medicine continues to play a role in kidney disease cases in Nigeria. "When you take herbal medication, you are taking both the good and the bad," he said. "Patients often arrive late, when treatment is more difficult and expensive." Dialysis alone can cost between 50,000 and 100,000 naira ($36-72) per session, several times a week. Studies link herbal use to kidney and liver disease cases across Africa, including findings that about 46 percent of liver disease admissions in one Nigerian hospital involved herbs or roots. A 2022 study found that 76.65 percent of participants had used herbal medicine, with more than a third combining herbal and conventional treatments while 82.44 percent did not inform their doctors. The Algorithmic Amplification Effect On a smartphone screen, relief is just a click away: fertility tonics, eye drops promising restored vision, syrups claiming to "flush out" disease. The advertisements are polished, persuasive and constant, woven into TikTok, Facebook, Instagram and X feeds. "The platforms themselves amplify this effect," said Dr Egemba Chinonso Fidelis, a public health advocate known online as Aproko Doctor. "Their algorithms reward engaging content and push it to wider audiences." Even users who try to avoid such content often encounter it repeatedly, shaped by emotional storytelling, music and urgency-driven messaging. A 2025 Nigeria-based study on Jinja Herbal Mixture found it appeared safe for short-term use within tested dosage ranges, but researchers recorded biochemical changes at higher doses, including altered creatinine and sodium levels in test subjects, signs of possible kidney and liver stress. The study called for further research into long-term effects and interactions with conventional medicines. Regulatory Challenges in the Digital Age The National Agency for Food and Drug Administration and Control (NAFDAC) says it is working to track unregistered manufacturers, but enforcement remains difficult, especially online. "With the sheer volume of products online, enforcement has limited reach," said Isaac Kolawole, the southwest zonal director of NAFDAC. Many sellers use fake or incomplete addresses, making them difficult to trace. NAFDAC requires strict registration, testing and approval before herbal products can be sold or advertised, but regulation has not kept pace with online commerce. Fidelis argued that stronger regulation alone is not enough. "If there are no consequences for lying about healthcare online, people will keep doing it," he said. He noted that scammers have even used AI-generated versions of his image to promote fake products. "Real medicine does not promise to cure everything, and it does not rely on countdowns," he added. "Scammers do." Path Forward for Safer Digital Health As Nigeria's digital economy expands, the intersection of technology and healthcare will only grow more complex. Fidelis stressed that access to affordable healthcare must improve, public trust must be rebuilt, and digital platforms must take responsibility for the health content they amplify. Pharmacist Akinade Akinlolu noted that while conditions like diabetes and hypertension can be managed, online claims often suggest cures. "Economic pressure is also pushing people towards cheaper or 'miracle' alternatives," he added. "Without stronger safeguards," Fidelis warned, "the algorithmic apothecary will continue to grow and put more people at risk." The challenge for Nigeria's healthcare system is to harness the power of digital platforms while ensuring they promote evidence-based care rather than potentially harmful alternatives.

The LeadMost men in the UK will not be offered prostate cancer screening if the government accepts the final recommendation of an expert committee. The UK National Screening Committee (UKNSC) has concluded that widespread screening using the prostate-specific antigen (PSA) test was "likely to cause more harm than good" despite prostate cancer being the most common cancer in the UK.The Recommendation DetailsThe committee recommended screening only for men with the BRCA2 gene variant who have a family history of certain cancers, suggesting they be screened every two years between the ages of 45 and 61. For this specific group, prostate cancer is more common, develops earlier, and can be more aggressive. Of 100 men with a BRCA2 variant, between 21 and 35 will develop prostate cancer before the age of 80.The committee recommended against screening for other at-risk groups, including black men, citing "ongoing uncertainty on whether screening would cause more good than harm." The main harms of population screening include incontinence and erectile dysfunction in men who do not need treatment for the disease.The Prevalence DataProstate cancer is the most common cancer in the UK, with more than 64,000 men diagnosed every year. However, there is currently no national screening programme for the disease. The UKNSC estimates that its final recommendation would lead to "a few thousand" men being screened for prostate cancer each year.Only around one in every 300 to 400 people will have BRCA gene variations, though as many as one in every 40 Ashkenazi Jewish people carry these variations. In England, the NHS offers free BRCA gene testing for anyone aged 18 or over who has at least one Jewish grandparent.The Impact AnalysisThe decision will come as a blow to campaigners who have voiced support for more widespread screening, including high-profile figures like Sir Chris Hoy, David Cameron, and Sir Stephen Fry. Prostate Cancer UK expressed being "deeply disappointed" with the recommendation, stating that without a screening programme for the UK's most common cancer, "we lose more than 12,000 dads, brothers and partners every single year."However, medical experts argue that screening can reduce deaths from prostate cancer only to a small extent and does not improve overall survival. The challenge remains that once a prostate cancer is found, doctors still can't reliably tell which cancers need treatment and which do not, and treatments can cause long-lasting harm.The Future OutlookThe government will now consider the recommendation, with the new Health Secretary James Murray set to meet with the UKNSC chair. The Department of Health and Social Care stated that Murray "will give full and careful consideration to the recommendation" and would update on the government's response shortly.The committee acknowledged that more research is needed to address evidence gaps, particularly regarding black men. The UKNSC will work with the Transform trial, launched by Prostate Cancer UK, to gather more data. It was noted as "particularly important" that a "sufficient number" of black men be invited to participate in this trial.

New research commissioned by Friends of the Earth Ireland and Beyond Fossil Fuels reveals that the rapid expansion of data centres in Ireland is silently inflating household electricity bills, creating what the authors call a "hidden data‑centre tax". Datacentre Power Surge Consumes 22% of Ireland’s Electricity According to the Central Statistics Office, data centres used 22% of the nation’s electricity last year – more than the combined consumption of all urban homes. By contrast, the United States and the United Kingdom each see data‑centre demand at roughly 6% of total electricity use. €715 million Drain and €360 Household Cost Spike (2015‑2023) €715 million has been extracted from the Irish economy as a net cost of data‑centre electricity demand. Average household bills rose by a cumulative €360 between 2015 and 2023. Modelling by Seán Fearon, post‑doctoral researcher at the Autonomous University of Barcelona, links the rise to increased hours where gas sets the system price. Ripple Effects on Irish Economy and European Energy Prices Jill McArdle of Beyond Fossil Fuels warns that Ireland’s experience is a warning sign for Europe: unchecked data‑centre growth can amplify energy‑price volatility, especially when combined with fossil‑gas dependence. Industry groups counter that data centres inject capital – €18 billion in recent years – and pay substantial corporate taxes, funding public infrastructure. Future Cost Trajectory: €295‑€644 per Household (2025‑2034) Fearon projects that, depending on growth rates, the average Irish household could incur an additional €295‑€644 in electricity costs over the 2025‑2034 decade, amounting to a national total between €633 million and €1.43 billion. Policy Outlook: Calls for EU Safeguards and Renewable Offsets Stakeholders urge the European Commission to tighten safeguards, ensuring new data centres are matched with renewable‑energy capacity. Without such measures, the sector could lock Europe into a “toxic mix” of high‑demand tech and volatile fossil‑gas pricing.

The Hidden Cost Excluding PhD Parents from Childcare SupportThe education secretary, Bridget Phillipson, has asked the Competition and Markets Authority to examine hidden childcare charges. At the same time, the Department for Education’s own eligibility criteria for the 30 hours of funded childcare leave a large group of doctoral researchers without support.Eligibility Rules That Bar PhD Stipend EarnersPhD students on a typical UK Research and Innovation‑funded course earn roughly £20,000 a year. Because their stipend does not meet the narrow definition of “income” used to qualify for the scheme, they are denied the benefit that most working families receive.Eligibility hinges on a technical income definition set by the Conservatives.The Department for Education suggested qualifying by adding 16 hours of part‑time work per week.£8,000 Gap and Income ThresholdsThe author estimates that a PhD‑parent family misses out on about £8,000 of childcare support over the eligible period. This shortfall represents a substantial portion of a household earning £20,000 annually.Funded childcare is intended for families with children under five, offering up to 30 hours per week.PhD stipends fall below the income threshold, despite the parents’ “working family” status.Consequences for Academic Talent and Family ChoicesWithout the support, many doctoral candidates face a dilemma between continuing their research and leaving the programme to seek paid employment. The loss of potential scientists and clinicians could weaken the UK’s research pipeline.Reduced diversity in higher‑education research staff.Potential brain‑drain as talented individuals seek more supportive environments abroad.Possible Policy Revisions Under a Labour AdministrationThe author argues that a future Labour government should broaden the definition of qualifying income and remove the “nerd tax”. A review by the CMA could pave the way for more inclusive criteria, aligning the scheme with its stated goal of supporting working families.Re‑evaluate income definitions to include stipend‑based earnings.Consider flexible work‑hour requirements that recognise doctoral research commitments.